Cargando…

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation

Osteoporosis is a major health problem in the elderly. Almost every bone can fracture due to the increased bone fragility in osteoporosis, posing a major challenge to public health. 12-Deoxyphorbol-13-hexadecanoate (DHD), one of the main bioactive components of Stellera chamaejasme L. (Lang Du), is...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qi, Yang, Junzheng, Chen, Delong, Li, Yejia, Gong, Dawei, Ge, Hui, Wang, Zihao, Wang, Haibin, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204068/
https://www.ncbi.nlm.nih.gov/pubmed/35721216
http://dx.doi.org/10.3389/fphar.2022.899776
_version_ 1784728834065563648
author He, Qi
Yang, Junzheng
Chen, Delong
Li, Yejia
Gong, Dawei
Ge, Hui
Wang, Zihao
Wang, Haibin
Chen, Peng
author_facet He, Qi
Yang, Junzheng
Chen, Delong
Li, Yejia
Gong, Dawei
Ge, Hui
Wang, Zihao
Wang, Haibin
Chen, Peng
author_sort He, Qi
collection PubMed
description Osteoporosis is a major health problem in the elderly. Almost every bone can fracture due to the increased bone fragility in osteoporosis, posing a major challenge to public health. 12-Deoxyphorbol-13-hexadecanoate (DHD), one of the main bioactive components of Stellera chamaejasme L. (Lang Du), is considered to have antitumor, antibacterial, and antifungal properties. However, the role of DHD in osteoporosis is still elusive. In this study, we demonstrated for the first time that DHD inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and bone resorption in a dose- and time-dependent manner without exhibiting cytotoxicity in vitro. Mechanistically, we found that DHD not only represses the expression of osteoclasts marker genes by suppressing RANKL-induced mitogen-activated protein kinase (MAPK) and calcium signaling pathways but also scavenges reactive oxygen species (ROS) through enhancing cytoprotective enzymes expression. Furthermore, DHD inhibits the activation of nuclear factor of activated T cells 1 (NFATc1) during RANKL-induced osteoclasts formation. Preclinical studies revealed that DHD protects against bone loss in ovariectomy (OVX) mice. In sum, our data confirmed that DHD could potentially inhibit osteoclastogenesis by abrogating RANKL-induced MAPK, calcium, and NFATc1 signaling pathways and promoting the expression of ROS scavenging enzymes, thereby preventing OVX-induced bone loss. Thus, DHD may act as a novel therapeutic agent to manage osteoporosis.
format Online
Article
Text
id pubmed-9204068
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92040682022-06-18 12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation He, Qi Yang, Junzheng Chen, Delong Li, Yejia Gong, Dawei Ge, Hui Wang, Zihao Wang, Haibin Chen, Peng Front Pharmacol Pharmacology Osteoporosis is a major health problem in the elderly. Almost every bone can fracture due to the increased bone fragility in osteoporosis, posing a major challenge to public health. 12-Deoxyphorbol-13-hexadecanoate (DHD), one of the main bioactive components of Stellera chamaejasme L. (Lang Du), is considered to have antitumor, antibacterial, and antifungal properties. However, the role of DHD in osteoporosis is still elusive. In this study, we demonstrated for the first time that DHD inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and bone resorption in a dose- and time-dependent manner without exhibiting cytotoxicity in vitro. Mechanistically, we found that DHD not only represses the expression of osteoclasts marker genes by suppressing RANKL-induced mitogen-activated protein kinase (MAPK) and calcium signaling pathways but also scavenges reactive oxygen species (ROS) through enhancing cytoprotective enzymes expression. Furthermore, DHD inhibits the activation of nuclear factor of activated T cells 1 (NFATc1) during RANKL-induced osteoclasts formation. Preclinical studies revealed that DHD protects against bone loss in ovariectomy (OVX) mice. In sum, our data confirmed that DHD could potentially inhibit osteoclastogenesis by abrogating RANKL-induced MAPK, calcium, and NFATc1 signaling pathways and promoting the expression of ROS scavenging enzymes, thereby preventing OVX-induced bone loss. Thus, DHD may act as a novel therapeutic agent to manage osteoporosis. Frontiers Media S.A. 2022-06-03 /pmc/articles/PMC9204068/ /pubmed/35721216 http://dx.doi.org/10.3389/fphar.2022.899776 Text en Copyright © 2022 He, Yang, Chen, Li, Gong, Ge, Wang, Wang and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
He, Qi
Yang, Junzheng
Chen, Delong
Li, Yejia
Gong, Dawei
Ge, Hui
Wang, Zihao
Wang, Haibin
Chen, Peng
12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
title 12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
title_full 12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
title_fullStr 12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
title_full_unstemmed 12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
title_short 12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
title_sort 12-deoxyphorbol-13-hexadecanoate abrogates ovx-induced bone loss in mice and osteoclastogenesis via inhibiting ros level and regulating rankl-mediated nfatc1 activation
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204068/
https://www.ncbi.nlm.nih.gov/pubmed/35721216
http://dx.doi.org/10.3389/fphar.2022.899776
work_keys_str_mv AT heqi 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation
AT yangjunzheng 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation
AT chendelong 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation
AT liyejia 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation
AT gongdawei 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation
AT gehui 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation
AT wangzihao 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation
AT wanghaibin 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation
AT chenpeng 12deoxyphorbol13hexadecanoateabrogatesovxinducedbonelossinmiceandosteoclastogenesisviainhibitingroslevelandregulatingranklmediatednfatc1activation